NEUP vs BIIB vs JPM

For growth investors, JPMorgan Chase & Co.

(JPM) is the stronger pick with 3. 3% revenue growth year-over-year, versus 1. 4% for Biogen Inc. (BIIB). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate Biogen Inc. (BIIB) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 2x versus Biogen Inc. at 22. 3x. On forward P/E, Biogen Inc. is actually cheaper at 13. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +135. 5%, compared to -97. 6% for Neuphoria Therapeutics Inc. (NEUP). Over 10 years, the gap is even starker: JPM returned +481. 2% versus NEUP's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Biogen Inc.

(BIIB) is the lower-risk stock at 0. 34β versus Neuphoria Therapeutics Inc. 's 1. 38β — meaning NEUP is approximately 302% more volatile than BIIB relative to the S&P 500. On balance sheet safety, Neuphoria Therapeutics Inc. (NEUP) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), JPMorgan Chase & Co.

(JPM) is pulling ahead at 3. 3% versus 1. 4% for Biogen Inc. (BIIB). On earnings-per-share growth, the picture is similar: JPMorgan Chase & Co. grew EPS 1. 5% year-over-year, compared to -130. 0% for Neuphoria Therapeutics Inc.. Over a 3-year CAGR, NEUP leads at 290. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -2. 4% for Neuphoria Therapeutics Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -7. 2% for NEUP. At the gross margin level — before operating expenses — NEUP leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Biogen Inc.

(BIIB) trades at 13. 5x forward P/E versus 14. 6x for JPMorgan Chase & Co. — 1. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BIIB: 11. 1% to $218. 32.

In this comparison, JPM (1.

8% yield) pays a dividend. NEUP, BIIB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 8% yield, +481. 2% 10Y return). Both have compounded well over 10 years (JPM: +481. 2%, NEUP: -97. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NEUP (Healthcare) and BIIB (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NEUP is a small-cap quality compounder stock; BIIB is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while NEUP, BIIB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.